Ordentlich Peter 4
4 · Syndax Pharmaceuticals Inc · Filed Feb 17, 2023
Insider Transaction Report
Form 4
Ordentlich Peter
Chief Technology Officer
Transactions
- Exercise/Conversion
Common Stock
2023-02-15$6.38/sh+7,572$48,309→ 7,572 total - Sale
Common Stock
2023-02-15$25.84/sh−7,572$195,688→ 0 total - Sale
Common Stock
2023-02-15$25.84/sh−17,428$450,404→ 0 total - Exercise/Conversion
Stock Options (Right to buy)
2023-02-15$25.84/sh−17,428$450,404→ 0 totalExercise: $7.20Exp: 2025-06-01→ Common Stock (17,428 underlying) - Exercise/Conversion
Common Stock
2023-02-15$7.20/sh+17,428$125,482→ 17,428 total - Exercise/Conversion
Stock Options (Right to buy)
2023-02-15$25.84/sh−7,572$195,688→ 0 totalExercise: $6.38Exp: 2029-02-06→ Common Stock (7,572 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 443,841 options to purchase shares of common stock that are vested and immediately exercisable and a total of 202,500 options to purchase shares of common stock that have not yet vested.
- [F2]The sale prices ranged from $25.53 to $26.10.
- [F3]This option is fully vested.